Human plasma kallikrein inhibitors
US-2021078952-A1 · Mar 18, 2021 · US
Human plasma kallikrein inhibitors
US11230530B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11230530-B2 |
| Application number | US-202016845833-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2020 |
| Priority date | Mar 7, 2014 |
| Publication date | Jan 25, 2022 |
| Grant date | Jan 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or preventing angioedema, comprising orally administering to a subject in need thereof an oral dosage form comprising a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the oral dosage form is administered once per day. 3. The method of claim 1 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day. 4. The method of claim 1 , wherein the angioedema is hereditary angioedema. 5. The method of claim 4 , wherein the oral dosage form is administered once per day. 6. The method of claim 4 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day. 7. The method of claim 1 , wherein the compound is the (+)-enantiomer. 8. The method of claim 7 , wherein the angioedema is hereditary angioedema. 9. The method of claim 7 , wherein the oral dosage form is administered once per day. 10. The method of claim 7 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day. 11. The method of claim 1 , wherein the compound is the (−)-enantiomer. 12. The method of claim 11 , wherein the angioedema is hereditary angioedema. 13. The method of claim 11 , wherein the oral dosage form is administered once per day. 14. The method of claim 11 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day. 15. The method of claim 1 , wherein the oral dosage form comprises a hydrochloride salt of the compound. 16. The method of claim 15 , wherein the angioedema is hereditary angioedema. 17. The method of claim 15 , wherein the oral dosage form is administered once per day. 18. The method of claim 15 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day. 19. The method of claim 1 , wherein the oral dosage form comprises a bis(hydrochloride) salt of the compound. 20. The method of claim 19 , wherein the angioedema is hereditary angioedema. 21. The method of claim 19 , wherein the oral dosage form is administered once per day. 22. The method of claim 19 , wherein the oral dosage form is a capsule and the oral dosage form is administered once per day.
Assignees
Inventors
Classifications
Drugs for disorders of the nervous system · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
containing three or more hetero rings · CPC title
Antihypertensives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11230530B2 cover?
- Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in …
- Who is the assignee on this patent?
- Biocryst Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).